Furthermore, a large anti-cytokine study [50] (CANTOS, www.thecantos.org), examined IL-1β inhibition via canakinumab, an IL-1β neutralizing monoclonal antibody, targeting decreased rates of recurrent MI, stroke, and cardiovascular death in patients with coronary artery disease and increased CRP. Here, IL1B is linked to coronary artery disorder.